FILING ANALYSIS · MONDAY, JUNE 22
Centessa Pharmaceuticals Adr 0ACX — RNS
positive
The High Court of Justice of England and Wales has approved Eli Lilly's acquisition of Centessa for $38.00 per share plus a contingent value right of up to $9.00, valuing the transaction at approximately $7.8 billion. The scheme of arrangement is expected to become effective on June 24, 2026
The filing
Centessa Pharmaceuticals Adr — Acquisition Of Centessa By Lilly Approved By
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →